Top

Making use of the Internet to increase, as much as possible, the number of people who can live longer and healthier lives, and to reduce, as much as possible, the amount of unnecessary medical costs.

CONTACT

Including investments before 1P1Y Fund
and investments by Preferential Allotment in the IPO process.

The WHY

Shifts for Healthcare

One in three people are over the age of 65 in Japan, with medical costs continuing to balloon to over 40 trillion yen.

Over the years, M3 has invested in healthcare related venture companies tackling this social problem, in line with its corporate mission of "making use of the Internet to increase, as much as possible, the number of people who can live longer and healthier lives, and to reduce, as much as possible, the amount of unnecessary medical costs,".

At this juncture, we have established the “1P1Y Fund” corporate venture fund in order to actualize the M3 mission.

Investments through this fund and utilization of resources across M3’s ecosystem will boost the development and new business creation across the ventures in the fund, ultimately to bring paradigm shifts within the medical community.

The HOW

M3’s History of
Added Value Provision

The 1P1Y Fund provides extensive additional value and collaboration with the M3 group in addition to funding, in order to support the strong growth of the invested companies.

Endorsement backed by M3's extensive expertise
within the healthcare industry

#1 in market capital growth rate amongst the top 100 companies in Japan.

Became the first company to be included across all companies established since the year 2000, to be included in the Nikkei 225 Index, in Oct 2019.

A globally recognized company

#1 ranking Japanese company (#5 globally) in the 2017 Forbes Most Innovative Growth Companies

True experience-based management advice

Management Strategy
  • Business recommendations based on expertise across areas such as internet businesses (including platform business) and healthcare businesses (including AI)
  • IPO and post-IPO growth management guidance based on M3's experience of its own establishment in 2000, IPO in 2004, and TSE1 listing in 2007
Equity Story and IR
  • Advice for compelling equity stories to maximize corporate value ahead of IPO
  • Domestic and overseas investor introductions, IR advice, IR material creation support, etc.
Strategic Alliances
  • Proficiency in strategic alliances with large corporates.
  • M&A advice based on M3’s extensive track record of corporate acquisitions (as both buyer and seller).

Business Value Creation

Concrete business value creation support using M3’s platform of over 6 million global physician members

Sales and Marketing
  • Market research (including idea and seeds feasibility and marketability assessment) and promotional activity utilizing tools such as m3.com
  • Sales support employing M3 group resources
Pharmaceuticals and Product Development
  • Regulatory counsel and support for rapid, low cost market launch of product
  • PMDA negotiation support
  • Clinical study and trial execution support
Overseas Expansion
  • Advice regarding overseas development (US, EU, China, India, etc.)
  • Collaboration with M3 group overseas entities
Human Resources
  • Support for recruitment of healthcare field professionals
  • Staff sourcing and exchanges across the M3 group

Engineering Aptitude Including AI Development

Engineers
  • CTO/VPoE and top engineering talent recruitment advice
  • Management support for engineer organizations
  • Suggestions and joint organization of engineers’ study group and networking activities
通常のベンチャーキャピタルとしての支援ももちろん対応

All of the above, in addition to traditional venture capital functionalities

No conflict of interest with M3

Autonomy of the invested company will be well-respected. The invested companies are free to exit with partners besides M3. M3 is in principle unlikely to purchase the invested company, unless requested by the invested company for such consideration.

Compatibility with M3

Compatibility with M3:[Good] Solve major social issues and have social impact. A platformer that can change the industry. / Serious management, committed to results. Enjoys relentless improvement. / High growth potential and speed. Listing on a stock exchange is a passing phase. [We are not bothered whether we have it or not. / Only want to make money. They always make excuses why they can't do it. / Listing is the goal. Compatibility with M3:[Good] Solve major social issues and have social impact. A platformer that can change the industry. / Serious management, committed to results. Enjoys relentless improvement. / High growth potential and speed. Listing on a stock exchange is a passing phase. [We are not bothered whether we have it or not. / Only want to make money. They always make excuses why they can't do it. / Listing is the goal.

1P1Y Fund Overview

Total Investment Line
10 billion yen (average of several hundred million yen per company to a maximum of approximately 2 billion yen)
Investment Region
Domestic and Global
Investment Target
Startups, Listed Companies, Pharmaceutical/Medical Device Pipelines, etc.
Investment Themes
Themes in which collaboration with M3 or M3 Group can be expected (AI, Medical Devices (including software), Advanced Medicine, Rare Diseases, Health Management, etc.)
Investment Target Stage
All Stages from Seed/Early to Late

PORTFOLIO

Striving to assist growth and new business creation through utilization of resources across the M3 group ecosystem

IPO

  • Includes investments before 1P1Y Fund
  • Includes investments by Preferential Allotment in the IPO process

Current Portfolio

Name for Startups, Inc.
Address Minato-ku, Tokyo, Japan
Business activities Growth industry support services
Name VALT JAPAN Inc.
Address Chiyoda-ku, Tokyo, Japan
Business activities Operating “NEXT HERO,” a DX platform specialized for potential workforce.
Name Sirka Science Pte. Ltd.
Address Indonesia
Business activities Chronic disease prevention and management platform
Name Chefaa
Address Egypt
Business activities e-Pharmacy
Name EcoNaviSta, Inc.
Address Chiyoda-ku, Tokyo, Japan
Business activities Development of AI for predicting health status transition through sleep analysis technology.
Name Kaigomedia Co., Ltd
Address Shibuya-ku, Tokyo, Japan
Business activities HR Platform Business, and digital marketing BusinessProfessionals.
Name HANOWA, Inc.
Address Osaka-shi, Osaka, Japan
Business activities Sharing Platform for Dental Professionals.
Name WizWe Corporation
Address Chiyoda-ku, Tokyo, Japan
Business activities Development and operation of habit-formation platform "Smart Habit."
Name Giver Link, Inc.
Address Sendai-shi, Miyagi, Japan
Business activities Operate the nursing care DX platform "Kaigo No Comimi", and develop multiple services to optimize information and commercial distribution in the nursing care industry.
Name Segmed, Inc.
Address Delaware, USA
Business activities Provide a data platform service that collects medical imaging data from medical institutions, anonymises and standardises it, and provides it to researchers and developers for the development of AI algorithms.
Name REGiMMUNE Limited.
Address Taipei 10352,Taiwan
Business activities Produce immune-regulatory therapeutics by regulating regulatory T cell (Treg).
Name alt Inc.
Address Minato-ku, Tokyo, Japan
Business activities Development and provision of P.A.I. (Personalized Artificial Intelligence).
Name Reliance Health, Inc.
Address Lagos, Nigeria
Business activities Affordable digital health insurance provider in Nigeria and emerging markets.
Name Rege Nephro Co., Ltd.
Address Sakyo-ku, Kyoto, JAPAN
Business activities R&D, production, and sales of therapeutic drugs for renal diseases.
Name Veritas In Silico Inc.
Address Shinagawa-ku, Tokyo, Japan
Business activities Platform business for the discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs.
Name SmartShopping, Inc.
Address Shinagawa-ku, Tokyo, JAPAN
Business activities Development and provision of a smart mat cloud to streamline inventory management.
Name C4U Corporation
Address Suita-shi, Osaka, JAPAN
Business activities Research and development utilizing CRISPR-Cas3, novel gene editing technologies.
Name Epigno Co., Ltd.
Address Minato-ku, Tokyo, JAPAN
Business activities Development and provision of human resources management solutions for medical and nursing home institutions.
Name EVERING Co.
Address Chuo-ku, Tokyo, Japan
Business activities Manufacture and sale of smart ring devices.
Name aptpod, Inc.
Address Shinjuku-ku, Tokyo, JAPAN
Business activities Provide a comprehensive framework for high-speed and large-volume data collection, transmission in the industrial scene.
Name Cardio Intelligence Inc.
Address Minato-ku, Tokyo, JAPAN
Business activities Development of Arrhythmia Diagnosis System Using Artificial Intelligence.
Name CarePoint (formerly Africa Health Holdings)
Address Cayman Islands
Business activities Management and operation of hospitals, clinics, pharmacies and laboratories in Africa
Name Perseus Proteomics Inc.
Address Chuo-ku, Tokyo, JAPAN
Business activities Development of antibody drugs.
Name Connect Inc.
Address Minato-ku, Tokyo, Japan
Business activities Development, manufacturing, and sales of brain-machine interface devices applied for neurorehabilitation.
Name CellAxia Inc.
Address Chuo-ku, Tokyo, Japan
Business activities Research and development of regenerative medicine.
Name PECO Inc.
Address Shibuya-ku, Tokyo, Japan
Business activities Management of one of the largest media specializing in pets in Japan, etc.
Name Shape Memory Medical Inc.
Address CA USA
Business activities Development of medical devices in the cardiovascular field.
Name Kringle Pharma, Inc.
Address Ibaraki, OSAKA, JAPAN
Business activities Research and development of HGF protein medicines.

Company Overview

Name
M3, Inc.
Address
Akasaka Intercity 10th floor 1-11-44 Akasaka Minato-ku, Tokyo 107-0052 JAPAN
Established
Sep 2000
Representative Director
Itaru Tanimura
Capital
29,192 million yen (as of end of Mar, 2023)
Listed Exchange
Tokyo Stock Exchange Prime Market (Securities code 2413)
Employees
10,533(group total as of the end of Mar, 2023)

NEWS

Mar 11, 2024
Investment in for Startups, Inc. (Ticker: 7089)
Feb 08, 2024
Veritas In Silico, Inc. lists on the TSE Growth Market (Ticker: 130A)
Jan 09, 2024
Investment in VALT JAPAN Inc.
Dec 27, 2023
Investment in Sirka Science Pte. Ltd.
Dec 18, 2023
Investment in Chefaa
Jul 26, 2023
EcoNaviSta, Inc. lists on the TSE Growth Market (Ticker: 5585)
Jul 21, 2023
Investment in EcoNaviSta, Inc.
May 19, 2023
Investment in Kaigomedia Co., Ltd
May 18, 2023
Investment in HANOWA, Inc.
Feb 07, 2023
Investment in WizWe Corporation
Dec 07, 2022
Investment in Giver Link, Inc.
Dec 01, 2022
Cyfuse Biomedical K.K. lists on the TSE Growth Market (Ticker: 4892)
Nov 15, 2022
Investment in Segmed, Inc.
Jul 01, 2022
Investment in REGiMMUNE Limited.
Jun 03, 2022
Investment in alt Inc.
Feb 07, 2022
Investment in Reliance Health, Inc.
Jan 31, 2022
Investment in Rege Nephro Co., Ltd.
Dec 27, 2021
Investment in Veritas In Silico Inc.
Dec 24, 2021
SUSMED, Inc lists on the TSE Mothers. (Ticker: 4263)
Dec 20, 2021
HYUGA PRIMARY CARE Co.,Ltd. lists on the TSE Mothers. (Ticker: 7133)
Nov 26, 2021
Investment in SmartShopping, Inc.
Aug 04, 2021
Investment in C4U Corporation
Jul 01, 2021
Capital Alliance with Epigno Co., Ltd ~ Accelerate DX of Talent Management for Medical Institutions ~
Jun 22, 2021
Perseus Proteomics Inc. lists on the TSE Mothers. (Ticker: 4882)
Apr 09, 2021
Investment in EVERING Co.
Mar 15, 2021
Investment in aptpod, Inc.
Mar 02, 2021
Investment in Cardio Intelligence Inc.
Mar 01, 2021
Capital Alliance with Africa Health Holdings Limited ~ Solution for Medical Facilities, Pharmacies and Laboratories in Africa ~
Dec 28, 2020
Kringle Pharma, Inc. lists on the TSE Mothers. (Ticker: 4884)
Nov 12, 2020
Joint Development and Distribution Agreement with Fuji Pharma
Nov 10, 2020
Investment in Perseus Proteomics Inc.
Oct 30, 2020
Investment in Connect Inc.
Sep 10, 2020
Investment in CellAxia Inc.
Aug 14, 2020
Investment in PECO Inc.
May 14, 2020
Investment in Shape Memory Medical, Inc.
Apr 22, 2020
Featured in The Nikkei
Apr 22, 2020
Full Scale Roll Out of CVC “1Y1P Fund” ~ Dedicated Website Launched to Fortify Investment Activity ~
Mar 2, 2020
Capital alliance with Kringle Pharma, Inc. ~ 7P Initiative: Development of Therapeutic Drugs for Spinal Cord Injury ~
Oct 25, 2019
Launch of Internal Corporate Venture Capital Fund “1P1Y (1 Person 1 Yen) Fund”

CONTACT

For any related inquiries, please email us, and our administrative office will revert.

Email address: 1p1y@m3.com

© 1P1Y. All Rights Reserved.